Skip to main content

Table 4 Comparison of incremental cost-effectiveness results for basecase and sensitivity analysis scenarios. All outcomes are accumulated over a lifetime horizon and are for the total population of Greater London. Cost savings are shown as negative values

From: The health, cost and equity impacts of restrictions on the advertisement of high fat, salt and sugar products across the transport for London network: a health economic modelling study

Outcome

Mean

Lower 95% CI

Upper 95% CI

TOTAL NHS & PSS COSTS

 Basecase

-£217,703,431

-£437,582,367

-£48,711,680

  SA1

-£226,718,104

-£475,058,585

-£37,773,383

  SA2

-£151,531,984

-£333,771,635

-£5,927,436

  SA3

-£107,991,545

-£255,351,553

£16,979,751

  SA4

-£393,625,146

-£752,241,459

-£138,109,426

  SA5

-£79,789,371

-£223,685,840

£40,117,017

QALYs

 Basecase

16,394

990

36,951

  SA1

17,377

814

40,812

  SA2

10,342

-4,268

27,952

  SA3

8,026

-2,991

21,643

  SA4

29,865

6,060

64,508

  SA5

5,997

-5,139

17,036

NET MONETARY BENEFIT (£20,000 per QALY THRESHOLD)

 Basecase

£545,591,744

£125,122,911

£1,088,464,368

  SA1

£574,259,454

£125,502,640

£1,199,502,240

  SA2

£358,372,911

£11,893,203

£840,304,073

  SA3

£268,518,915

£3,417,367

£602,086,044

  SA4

£990,928,187

£336,178,002

£1,917,914,385

  SA5

£199,739,062

-£49,302,909

£462,881,219

  1. QALY Quality-adjusted life-year, NMB Net monetary benefit, SA Sensitivity analysis, SA1 No socioeconomic gradient in calorie reduction, SA2 No indirect metabolic effects, SA3 Half calorie reduction, SA4 3 year duration of effect, SA5 1 year return to baseline BMI